Biomarker testing will play a key role in moving precision medicine forward in 2024, says Lyn Fitzgerald, Ontada's VP Sales Oncology Data, Evidence & Insights. Precise RWD insights will be pivotal in identifying and testing the right patients at the right time. Watch the full interview.
Solutions
![right arrow](/Ontada/images/icons/white-down-arrow.png?v=u3hjhmpNIp8etEtmS7upEeqmDPfsRubUgmP7L488NAo)
Life Sciences
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
News & Events
![right arrow](/Ontada/images/icons/blue-right-arrow.png?v=4KFZ6vCSu6sqTp58mSQjR0Tul-I-DKOrhnC2bAf3LXY)
More